Company Overview of Actavis Pharma, Inc.
Actavis Pharma, Inc. develops, manufactures, and markets generic pharmaceutical products. It offers solid dosage and sterile dosage generic products. The company was formerly known as Schein Pharmaceutical, Inc. The company was founded in 1931 and is based in Parsippany, New Jersey. As of August 28, 2000, Actavis Pharma, Inc. operates as a subsidiary of Actavis plc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054
Founded in 1931
Key Executives for Actavis Pharma, Inc.
Senior Vice President of Strategic Development
Senior Vice President of Technical Operations
Compensation as of Fiscal Year 2014.
Actavis Pharma, Inc. Key Developments
Galena Biopharma's Partner Orexo Files Patent Infringement Suit Against Actavis Laboratories, Andrx Corporation, Actavis, Inc. and Actavis Pharma
Feb 5 15
Galena Biopharma (GALE) announced that its partner Orexo has filed a patent infringement lawsuit in United States District Court for the District of New Jersey, against Actavis Laboratories, Andrx Corporation, Actavis Inc. (ACT) and Actavis Pharma for seeking to market a generic version of its Abstral drug. The lawsuit was filed in response to an Abbreviated New Drug Application filed by Actavis. In its application, Actavis seeks to market and sell generic versions of Abstral sublingual tablets in the U.S. prior to the expiration of Orexo's U.S. patents.
Supernus Pharmaceuticals, Inc. Sues Actavis plc, Actavis, Inc., Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. for Infringement of Three Patents
Oct 2 14
Supernus Pharmaceuticals, Inc. announced that it sued Actavis plc, Actavis, Inc., Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. (collectively 'Actavis') for infringement of three patents covering its antiepileptic drug Trokendi XR(R). Supernus' United States Patents Nos. 8,298,576, 8,298,580, and 8,663,683 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR(R) does not expire until 2029. The Complaint--filed in the U.S. District Court for the District of New Jersey--alleges that Actavis infringed Supernus' Trokendi XR(R) patents by submitting to the Food and Drug Administration an Abbreviated New Drug Application ('ANDA') seeking to market a generic version of Trokendi XR(R) prior to the expiration of Supernus' patents. Filing its Complaint within 45 days of receiving Actavis' Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Actavis' ANDA for 30 months.
Actavis Pharma Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014
Apr 30 14
Actavis Pharma reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net revenues of $2,264.9 million compared to $1,664.5 million a year ago. Adjusted gross profit was $1,406.2 million compared to $883 million a year ago. Net revenue increased 36% due to the acquisition of Warner Chilcott, new product launches, and higher international net revenue. Adjusted gross margin as a percentage of adjusted net revenues within Actavis Pharma increased to 65.3% in the first quarter of 2014 from 52.7% in the first quarter of 2013, as a result of the acquisition of Warner Chilcott in the fourth quarter of 2013. Adjusted net revenues were $2,152.82 million compared to $1,674.3 million a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|